{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:20:09Z","timestamp":1788175209148,"version":"build-2803163510"},"reference-count":140,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bladder cancer (BCa), marked by clinical heterogeneity and late diagnosis, remains a global health challenge. The limitations of conventional diagnostics have spurred the advancement of liquid biopsy approaches, which offer minimally invasive tools for early detection, prognosis, and therapeutic monitoring. This review highlights key components of liquid biopsy in BCa, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and metabolomics\u2014especially urinary volatile organic compounds (VOCs). Each modality contributes distinct insights into tumor biology: CTCs and ctDNA provide information on tumor genetics and dynamics; exosomes reflect microenvironmental signaling and lipid metabolism; and urinary VOC profiling enables metabolic characterization and early-stage discrimination. We explore how these dimensions complement each other in tracking disease progression, predicting recurrence, and guiding personalized therapy. Emphasis is placed on recent technological advances, clinical utility, and future integration into practice. This multidimensional perspective underscores the transformative potential of liquid biopsy in improving BCa outcomes.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf409","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:27:10Z","timestamp":1768912030000},"source":"Crossref","is-referenced-by-count":4,"title":["Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4803-0833","authenticated-orcid":false,"given":"Dianjie","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Xiangya Hospital at Central South University , Changsha 410011, Hunan,","place":["China"]},{"name":"Xiangya School of Medicine, Central South University , Changsha, Hunan 410078,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojian","family":"Liu","sequence":"additional","affiliation":[{"name":"Xiangya School of Medicine, Central South University , Changsha, Hunan 410078,","place":["China"]},{"name":"Xiangya Hospital, Central South University , Changsha, Hunan 410008,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Xiangya Hospital at Central South University , Changsha 410011, Hunan,","place":["China"]},{"name":"Department of Nephrology, The Second Xiangya Hospital at Central South University , Changsha, 410011,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhuai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Xiangya Hospital at Central South University , Changsha 410011, Hunan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0263-3704","authenticated-orcid":false,"given":"Jiachen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Xiangya Hospital at Central South University , Changsha 410011, Hunan,","place":["China"]},{"name":"Xiangya Hospital, Central South University , Changsha, Hunan 410008,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Xiangya Hospital at Central South University , Changsha 410011, Hunan,","place":["China"]},{"name":"Department of Nephrology, The Second Xiangya Hospital at Central South University , Changsha, 410011,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2026012911014300300_oyaf409-B1","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"2026012911014300300_oyaf409-B2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2026012911014300300_oyaf409-B3","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2026012911014300300_oyaf409-B4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B5","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026012911014300300_oyaf409-B6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"2026012911014300300_oyaf409-B7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.042","article-title":"The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks","volume":"70","author":"Cumberbatch","year":"2016","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B9","doi-asserted-by":"crossref","first-page":"m2942","DOI":"10.1136\/bmj.m2942","article-title":"Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study","volume":"370","author":"Zhang","year":"2020","journal-title":"BMJ"},{"key":"2026012911014300300_oyaf409-B10","doi-asserted-by":"crossref","first-page":"13254","DOI":"10.1021\/acs.est.2c05178","article-title":"Promotion of bladder cancer cell metastasis by 2-mercaptobenzothiazole via its activation of aryl hydrocarbon receptor transcription: molecular dynamics simulations, cell-based assays, and machine learning-driven prediction","volume":"56","author":"Zhang","year":"2022","journal-title":"Environ Sci Technol"},{"key":"2026012911014300300_oyaf409-B11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhazmat.2008.03.070","article-title":"Leather waste\u2014potential threat to human health, and a new technology of its treatment","volume":"160","author":"Kolomaznik","year":"2008","journal-title":"J Hazard Mater"},{"key":"2026012911014300300_oyaf409-B12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajim.20469","article-title":"Bladder cancer and occupation: a report from the belgian case-control study on bladder cancer risk","volume":"50","author":"Reulen","year":"2007","journal-title":"Am J Ind Med"},{"key":"2026012911014300300_oyaf409-B13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/10408440903352826","article-title":"Meta-analyses of occupational exposure as a painter and lung and bladder cancer morbidity and mortality 1950-2008","volume":"40","author":"Bachand","year":"2010","journal-title":"Crit Rev Toxicol"},{"key":"2026012911014300300_oyaf409-B14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CJI.0b013e3181d32e74","article-title":"Cancer and inflammation: promise for biologic therapy","volume":"33","author":"Demaria","year":"2010","journal-title":"J Immunother"},{"key":"2026012911014300300_oyaf409-B15","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/ijc.32842","article-title":"Urinary tract infections and risk of squamous cell carcinoma bladder cancer: a danish nationwide case-control study","volume":"146","author":"Potteg\u00e5rd","year":"2020","journal-title":"Int J Cancer"},{"key":"2026012911014300300_oyaf409-B16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00240-017-1033-7","article-title":"The risk of bladder cancer in patients with urinary calculi: a meta-analysis","volume":"46","author":"Yu","year":"2018","journal-title":"Urolithiasis"},{"key":"2026012911014300300_oyaf409-B17","doi-asserted-by":"crossref","first-page":"586401","DOI":"10.3389\/fonc.2020.586401","article-title":"Risk and prognosis of secondary bladder cancer after radiation therapy for rectal cancer: a large population-based cohort study","volume":"10","author":"Guan","year":"2020","journal-title":"Front Oncol"},{"key":"2026012911014300300_oyaf409-B18","first-page":"Cd010908","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012911014300300_oyaf409-B19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/humupd\/dmy027","article-title":"Ureteral endometriosis: a systematic review of epidemiology, pathogenesis, diagnosis, treatment, risk of malignant transformation and fertility","volume":"24","author":"Barra","year":"2018","journal-title":"Hum Reprod Update"},{"key":"2026012911014300300_oyaf409-B20","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"2026012911014300300_oyaf409-B21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B23","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"2026012911014300300_oyaf409-B24","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3399\/BJGP.2021.0319","article-title":"Risk prediction models for symptomatic patients with bladder and kidney cancer: a systematic review","volume":"72","author":"Harrison","year":"2022","journal-title":"Br J Gen Pract"},{"key":"2026012911014300300_oyaf409-B25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2017.09.030","article-title":"The role of surgery in metastatic bladder cancer: a systematic review","volume":"73","author":"Abufaraj","year":"2018","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eururo.2017.04.018","article-title":"Bladder cancer in the elderly","volume":"73","author":"Babjuk","year":"2018","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","article-title":"Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and asia","volume":"47","author":"Tan","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"2026012911014300300_oyaf409-B28","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2026012911014300300_oyaf409-B29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-018-0105-y","article-title":"T1 bladder cancer: current considerations for diagnosis and management","volume":"16","author":"Jordan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"2026012911014300300_oyaf409-B30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.eururo.2011.01.014","article-title":"Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy","volume":"59","author":"Feifer","year":"2011","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"2026012911014300300_oyaf409-B32","doi-asserted-by":"crossref","first-page":"100785","DOI":"10.1016\/j.xcrm.2022.100785","article-title":"Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study","volume":"3","author":"Hu","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026012911014300300_oyaf409-B33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ctrv.2017.12.007","article-title":"Immune checkpoint inhibitors for metastatic bladder cancer","volume":"64","author":"Massari","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2026012911014300300_oyaf409-B35","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat Commun"},{"key":"2026012911014300300_oyaf409-B36","doi-asserted-by":"crossref","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"2026012911014300300_oyaf409-B37","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.19.00861","article-title":"Phase II California cancer consortium trial of Gemcitabine-Eribulin combination in Cisplatin-Ineligible patients with metastatic urothelial carcinoma: Final report (NCI-9653)","volume":"37","author":"Sadeghi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026012911014300300_oyaf409-B38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by Ultra-Deep sequencing of plasma Cell-Free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026012911014300300_oyaf409-B39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1159\/000052519","article-title":"The early detection and diagnosis of bladder cancer: a critical review of the options","volume":"39","author":"Saad","year":"2001","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","article-title":"Urine biomarkers in bladder cancer\u2014current status and future perspectives","volume":"20","author":"Maas","year":"2023","journal-title":"Nat Rev Urol"},{"key":"2026012911014300300_oyaf409-B41","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2214\/AJR.16.17114","article-title":"Role of imaging in the local staging of urothelial carcinoma of the bladder","volume":"208","author":"Lee","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"2026012911014300300_oyaf409-B42","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.7150\/ijms.19929","article-title":"Urinary UBC rapid and NMP22 test for bladder cancer surveillance in comparison to urinary cytology: results from a prospective Single-Center study","volume":"14","author":"Pichler","year":"2017","journal-title":"Int J Med Sci"},{"key":"2026012911014300300_oyaf409-B44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.7326\/M15-0997","article-title":"Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis","volume":"163","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026012911014300300_oyaf409-B45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"2026012911014300300_oyaf409-B46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-024-01974-4","article-title":"Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial","volume":"23","author":"Wu","year":"2024","journal-title":"Mol Cancer"},{"key":"2026012911014300300_oyaf409-B47","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1097\/JS9.0000000000000592","article-title":"Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: a systematic review and network meta-analysis","volume":"109","author":"Fan","year":"2023","journal-title":"Int J Surg"},{"key":"2026012911014300300_oyaf409-B48","doi-asserted-by":"crossref","first-page":"e218409","DOI":"10.1001\/jamanetworkopen.2021.8409","article-title":"Assessment of diagnostic yield of cystoscopy and computed tomographic urography for urinary tract cancers in patients evaluated for microhematuria: a systematic review and meta-analysis","volume":"4","author":"Waisbrod","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026012911014300300_oyaf409-B49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaoncol.2024.6160","article-title":"Urinary DNA methylation test for bladder cancer diagnosis","volume":"11","author":"Jeong","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026012911014300300_oyaf409-B50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3233\/BLC-180179","article-title":"Urinary biomarkers in the evaluation of primary hematuria: a systematic review and Meta-Analysis","volume":"4","author":"Sathianathen","year":"2018","journal-title":"Bladder Cancer"},{"key":"2026012911014300300_oyaf409-B51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026012911014300300_oyaf409-B52","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026012911014300300_oyaf409-B53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-021-01392-w","article-title":"Using single-cell sequencing technology to detect circulating tumor cells in solid tumors","volume":"20","author":"Xu","year":"2021","journal-title":"Mol Cancer"},{"key":"2026012911014300300_oyaf409-B54","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/cncr.22543","article-title":"Detection of circulating urothelial cancer cells in the blood using the CellSearch system","volume":"109","author":"Naoe","year":"2007","journal-title":"Cancer"},{"key":"2026012911014300300_oyaf409-B55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/annonc\/mdn627","article-title":"Detection of circulating tumor cells in patients with urothelial cancer","volume":"20","author":"Gallagher","year":"2009","journal-title":"Ann Oncol"},{"key":"2026012911014300300_oyaf409-B56","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/j.1464-410X.2010.09562.x","article-title":"Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer","volume":"107","author":"Rink","year":"2011","journal-title":"BJU Int"},{"key":"2026012911014300300_oyaf409-B57","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/annonc\/mdr619","article-title":"Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis","volume":"23","author":"Gazzaniga","year":"2012","journal-title":"Ann Oncol"},{"key":"2026012911014300300_oyaf409-B58","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026012911014300300_oyaf409-B59","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.eururo.2012.01.017","article-title":"Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study","volume":"61","author":"Rink","year":"2012","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B60","doi-asserted-by":"crossref","first-page":"101036","DOI":"10.1016\/j.neo.2024.101036","article-title":"Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics","volume":"57","author":"Niu","year":"2024","journal-title":"Neoplasia"},{"key":"2026012911014300300_oyaf409-B61","first-page":"176","article-title":"Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions","volume":"71","author":"Cheng","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026012911014300300_oyaf409-B62","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","article-title":"Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes","volume":"26","author":"Nuzzo","year":"2020","journal-title":"Nat Med"},{"key":"2026012911014300300_oyaf409-B63","doi-asserted-by":"crossref","first-page":"e17282","DOI":"10.15252\/emmm.202217282","article-title":"Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing","volume":"15","author":"van der Pol","year":"2023","journal-title":"EMBO Mol Med"},{"key":"2026012911014300300_oyaf409-B64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.eururo.2024.10.014","article-title":"Sensitive detection of urothelial cancer via high-volume urine DNA analysis","volume":"87","author":"Nikkola","year":"2025","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B65","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2024.01.016","article-title":"Circulating tumour DNA detection by the Urine-Informed analysis of archival serum samples from Muscle-Invasive bladder cancer patients","volume":"85","author":"BinHumaid","year":"2024","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B66","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ucl.2022.09.010","article-title":"Circulating tumor cells and circulating tumor DNA in urologic cancers","volume":"50","author":"Madueke","year":"2023","journal-title":"Urol Clin North Am"},{"key":"2026012911014300300_oyaf409-B67","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"key":"2026012911014300300_oyaf409-B68","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"2026012911014300300_oyaf409-B69","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","article-title":"Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma","volume":"126","author":"Shohdy","year":"2022","journal-title":"Br J Cancer"},{"key":"2026012911014300300_oyaf409-B70","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1093\/oncolo\/oyac037","article-title":"Longitudinal evaluation of circulating tumor DNA using sensitive amplicon-based next-generation sequencing to identify resistance mechanisms to immune checkpoint inhibitors for advanced urothelial carcinoma","volume":"27","author":"Ravi","year":"2022","journal-title":"Oncologist"},{"key":"2026012911014300300_oyaf409-B71","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911732","article-title":"Cell-Free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer","volume":"23","author":"Carrasco","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026012911014300300_oyaf409-B72","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B73","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"2026012911014300300_oyaf409-B74","doi-asserted-by":"crossref","first-page":"657483","DOI":"10.3389\/fonc.2021.657483","article-title":"Circulating tumor DNA analyses predict disease recurrence in Non-Muscle-Invasive bladder cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"2026012911014300300_oyaf409-B75","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2019.02.004","article-title":"Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study","volume":"3","author":"Grivas","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"2026012911014300300_oyaf409-B76","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B77","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B78","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026012911014300300_oyaf409-B79","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026012911014300300_oyaf409-B80","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association of plasma and urinary mutant DNA with clinical outcomes In muscle invasive bladder cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci Rep"},{"key":"2026012911014300300_oyaf409-B81","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy","volume":"23","author":"Khagi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026012911014300300_oyaf409-B82","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Birkenkamp-Demtr\u00f6der","year":"2016","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B83","first-page":"779","article-title":"Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study","volume":"33","author":"Hauser","year":"2013","journal-title":"Anticancer Res"},{"key":"2026012911014300300_oyaf409-B84","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/147323001103900119","article-title":"Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma","volume":"39","author":"Lin","year":"2011","journal-title":"J Int Med Res"},{"key":"2026012911014300300_oyaf409-B85","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.juro.2007.08.091","article-title":"Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer","volume":"179","author":"Ellinger","year":"2008","journal-title":"J Urol"},{"key":"2026012911014300300_oyaf409-B86","first-page":"980","article-title":"p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients","volume":"8","author":"Dom\u00ednguez","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2026012911014300300_oyaf409-B87","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0302-2838(02)00468-2","article-title":"Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer","volume":"42","author":"Valenzuela","year":"2002","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B88","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"2026012911014300300_oyaf409-B89","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"2026012911014300300_oyaf409-B90","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/diagnostics14090912","article-title":"Advancing evidence generation for circulating tumor DNA: Lessons learned from a Multi-Assay study of baseline circulating tumor DNA levels across cancer types and stages","volume":"14","author":"McKelvey","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026012911014300300_oyaf409-B91","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"2026012911014300300_oyaf409-B92","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"2026012911014300300_oyaf409-B93","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.2147\/IJN.S458397","article-title":"Bladder cancer in exosomal perspective: unraveling new regulatory mechanisms","volume":"19","author":"Yin","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"2026012911014300300_oyaf409-B94","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12951-023-02130-8","article-title":"Exosome, the glass slipper for cinderella of cancer-bladder cancer?","volume":"21","author":"Yang","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"2026012911014300300_oyaf409-B95","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ymthe.2022.01.022","article-title":"Exosome-derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments","volume":"30","author":"Yang","year":"2022","journal-title":"Mol Ther"},{"key":"2026012911014300300_oyaf409-B96","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/cbin.11292","article-title":"Exosomal miR-663b targets Ets2-repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells","volume":"44","author":"Yin","year":"2020","journal-title":"Cell Biol Int"},{"key":"2026012911014300300_oyaf409-B97","first-page":"6277","article-title":"MiR-4644 is upregulated in plasma exosomes of bladder cancer patients and promotes bladder cancer progression by targeting UBIAD1","volume":"12","author":"Yan","year":"2020","journal-title":"Am J Transl Res"},{"key":"2026012911014300300_oyaf409-B98","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1002\/cam4.3263","article-title":"Exosome-transmitted microRNA-133b inhibited bladder cancer proliferation by upregulating dual-specificity protein phosphatase 1","volume":"9","author":"Cai","year":"2020","journal-title":"Cancer Med"},{"key":"2026012911014300300_oyaf409-B99","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3390\/cancers12061507","article-title":"Small non-coding RNA profiling in plasma extracellular vesicles of bladder cancer patients by next-generation sequencing: expression levels of miR-126-3p and piR-5936 increase with higher histologic grades","volume":"12","author":"Sabo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026012911014300300_oyaf409-B100","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.31557\/APJCP.2019.20.7.2219","article-title":"Urine and serum exosomes as novel biomarkers in detection of bladder cancer","volume":"20","author":"Elsharkawi","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026012911014300300_oyaf409-B101","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/jcmm.14042","article-title":"Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"2026012911014300300_oyaf409-B102","doi-asserted-by":"crossref","first-page":"9307","DOI":"10.12659\/MSM.912018","article-title":"Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis","volume":"24","author":"Wang","year":"2018","journal-title":"Med Sci Monit"},{"key":"2026012911014300300_oyaf409-B103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-018-0880-3","article-title":"Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression","volume":"17","author":"Zheng","year":"2018","journal-title":"Mol Cancer"},{"key":"2026012911014300300_oyaf409-B104","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1158\/1078-0432.CCR-18-1270","article-title":"PRMT5 circular RNA promotes metastasis of urothelial carcinoma of the bladder through sponging miR-30c to induce Epithelial-Mesenchymal transition","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026012911014300300_oyaf409-B105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-017-0714-8","article-title":"Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1","volume":"16","author":"Xue","year":"2017","journal-title":"Mol Cancer"},{"key":"2026012911014300300_oyaf409-B106","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13046-025-03330-w","article-title":"Exosome-transmitted LUCAT1 promotes stemness transformation and chemoresistance in bladder cancer by binding to IGF2BP2","volume":"44","author":"Zhan","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"2026012911014300300_oyaf409-B107","doi-asserted-by":"crossref","first-page":"167627","DOI":"10.1016\/j.bbadis.2024.167627","article-title":"Exosomal miR-184 facilitates bladder cancer progression by targeting AKR1C3 and inducing immune escape via IRF2-CXCL10 axis","volume":"1871","author":"Ying","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2026012911014300300_oyaf409-B108","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41698-025-00859-z","article-title":"Exosomes containing miR-152-3p targeting FGFR3 mediate SLC7A7-induced angiogenesis in bladder cancer","volume":"9","author":"Cao","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026012911014300300_oyaf409-B109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s11658-023-00442-z","article-title":"Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer","volume":"28","author":"Li","year":"2023","journal-title":"Cell Mol Biol Lett"},{"key":"2026012911014300300_oyaf409-B110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejps.2016.10.008","article-title":"Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression","volume":"98","author":"Andreu","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"2026012911014300300_oyaf409-B111","doi-asserted-by":"crossref","first-page":"e0147236","DOI":"10.1371\/journal.pone.0147236","article-title":"Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes","volume":"11","author":"Berrondo","year":"2016","journal-title":"PLoS One"},{"key":"2026012911014300300_oyaf409-B112","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.juro.2012.07.094","article-title":"Diagnostic potential of urinary \u03b11-antitrypsin and apolipoprotein E in the detection of bladder cancer","volume":"188","author":"Urquidi","year":"2012","journal-title":"J Urol"},{"key":"2026012911014300300_oyaf409-B113","doi-asserted-by":"crossref","first-page":"34446","DOI":"10.1038\/srep34446","article-title":"Proteome profiling of urinary exosomes identifies alpha 1-Antitrypsin and H2B1K as diagnostic and prognostic biomarkers for urothelial carcinoma","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"key":"2026012911014300300_oyaf409-B114","doi-asserted-by":"crossref","first-page":"217352","DOI":"10.1016\/j.canlet.2024.217352","article-title":"Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer","volume":"609","author":"Steiner","year":"2025","journal-title":"Cancer Lett"},{"key":"2026012911014300300_oyaf409-B115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1631\/jzus.B2000711","article-title":"Exosomes in bladder cancer: novel biomarkers and targets","volume":"22","author":"Geng","year":"2021","journal-title":"J Zhejiang Univ Sci B"},{"key":"2026012911014300300_oyaf409-B116","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12964-021-00768-1","article-title":"Cancer derived exosomes induce macrophages immunosuppressive polarization to promote bladder cancer progression","volume":"19","author":"Jiang","year":"2021","journal-title":"Cell Commun Signal"},{"key":"2026012911014300300_oyaf409-B117","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12943-018-0846-5","article-title":"Transcriptome reprogramming by cancer exosomes: identification of novel molecular targets in matrix and immune modulation","volume":"17","author":"Qadir","year":"2018","journal-title":"Mol Cancer"},{"key":"2026012911014300300_oyaf409-B118","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cytogfr.2023.05.002","article-title":"Exosomes-regulated lipid metabolism in tumorigenesis and cancer progression","volume":"73","author":"Ye","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026012911014300300_oyaf409-B119","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41419-022-04506-4","article-title":"Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026012911014300300_oyaf409-B120","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3390\/pharmaceutics15051465","article-title":"Exosomes: diagnostic and therapeutic implications in cancer","volume":"15","author":"Jo","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026012911014300300_oyaf409-B121","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2016.10.011","article-title":"Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers","volume":"70","author":"Skotland","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026012911014300300_oyaf409-B122","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","article-title":"Emerging role of exosomes in cancer progression and tumor microenvironment remodeling","volume":"15","author":"Paskeh","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026012911014300300_oyaf409-B123","doi-asserted-by":"crossref","first-page":"e12471","DOI":"10.1002\/jev2.12471","article-title":"Extracellular vesicles originating from melanoma cells promote dysregulation in haematopoiesis as a component of cancer immunoediting","volume":"13","author":"Mamand","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"2026012911014300300_oyaf409-B124","doi-asserted-by":"crossref","first-page":"e270050","DOI":"10.1002\/jev2.70050","article-title":"Nanoscopic profiling of small extracellular vesicles via High-Speed atomic force microscopy (HS-AFM) videography","volume":"14","author":"Sandira","year":"2025","journal-title":"J Extracell Vesicles"},{"key":"2026012911014300300_oyaf409-B125","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00395-022-00950-7","article-title":"Acid sphingomyelinase deactivation post-ischemia promotes brain angiogenesis and remodeling by small extracellular vesicles","volume":"117","author":"Mohamud Yusuf","year":"2022","journal-title":"Basic Res Cardiol"},{"key":"2026012911014300300_oyaf409-B126","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.3390\/ijms25168605","article-title":"Involvement of expression of miR33-5p and ABCA1 in human peripheral blood mononuclear cells in coronary artery disease","volume":"25","author":"Torres-Paz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026012911014300300_oyaf409-B127","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13048-020-0609-y","article-title":"Proteomic and lipidomic analysis of exosomes derived from ovarian cancer cells and ovarian surface epithelial cells","volume":"13","author":"Cheng","year":"2020","journal-title":"J Ovarian Res"},{"key":"2026012911014300300_oyaf409-B128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41388-020-01486-7","article-title":"Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1","volume":"40","author":"Jia","year":"2021","journal-title":"Oncogene"},{"key":"2026012911014300300_oyaf409-B129","doi-asserted-by":"crossref","first-page":"034001","DOI":"10.1088\/1752-7155\/8\/3\/034001","article-title":"The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva","volume":"8","author":"Amann","year":"2014","journal-title":"J Breath Res"},{"key":"2026012911014300300_oyaf409-B130","doi-asserted-by":"crossref","first-page":"125296","DOI":"10.1016\/j.talanta.2023.125296","article-title":"Exploiting volatile fingerprints for bladder cancer diagnosis: a scoping review of metabolomics and sensor-based approaches","volume":"268","author":"Carapito","year":"2024","journal-title":"Talanta"},{"key":"2026012911014300300_oyaf409-B131","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41416-022-01785-8","article-title":"Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer","volume":"127","author":"Lett","year":"2022","journal-title":"Br J Cancer"},{"key":"2026012911014300300_oyaf409-B132","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00345-022-04136-7","article-title":"LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer","volume":"40","author":"Oto","year":"2022","journal-title":"World J Urol"},{"key":"2026012911014300300_oyaf409-B133","doi-asserted-by":"crossref","first-page":"e16686","DOI":"10.1016\/j.heliyon.2023.e16686","article-title":"Volatile organic compounds for early detection of prostate cancer from urine","volume":"9","author":"Liu","year":"2023","journal-title":"Heliyon"},{"key":"2026012911014300300_oyaf409-B134","doi-asserted-by":"crossref","first-page":"17170","DOI":"10.1021\/acs.analchem.3c02523","article-title":"Global urinary volatolomics with (GC\u00d7)GC-TOF-MS","volume":"95","author":"Myridakis","year":"2023","journal-title":"Anal Chem"},{"key":"2026012911014300300_oyaf409-B135","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3390\/cancers12082017","article-title":"A panel of urinary volatile biomarkers for differential diagnosis of prostate cancer from other urological cancers","volume":"12","author":"Lima","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026012911014300300_oyaf409-B136","first-page":"256","article-title":"Urinary VOCs as bladder cancer biomarkers","volume":"19","author":"Stone","year":"2022","journal-title":"Nat Rev Urol"},{"key":"2026012911014300300_oyaf409-B137","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humpath.2022.06.006","article-title":"Precursors of urinary bladder cancer: molecular alterations and biomarkers","volume":"133","author":"Taylor","year":"2023","journal-title":"Hum Pathol"},{"key":"2026012911014300300_oyaf409-B138","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/bios11110437","article-title":"Urinary volatiles and chemical characterisation for the Non-Invasive detection of prostate and bladder cancers","volume":"11","author":"Tyagi","year":"2021","journal-title":"Biosensors (Basel)"},{"key":"2026012911014300300_oyaf409-B139","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/metabo11040199","article-title":"Discovery of volatile biomarkers for bladder cancer detection and staging through urine metabolomics","volume":"11","author":"Pinto","year":"2021","journal-title":"Metabolites"},{"key":"2026012911014300300_oyaf409-B140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1039\/C0AN00382D","article-title":"Evaluation of a gas sensor array and pattern recognition for the identification of bladder cancer from urine headspace","volume":"136","author":"Weber","year":"2011","journal-title":"Analyst"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf409\/66579358\/oyaf409.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf409\/66579358\/oyaf409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf409\/66579358\/oyaf409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:02:04Z","timestamp":1769702524000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf409\/8441233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf409","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,17]]},"article-number":"oyaf409"}}